argus.hq — daily brief
3 recent FDA Warning Letters.
Live from Argus HQ’s own ingestion feed — not a demo.
critical · Center for Drug Evaluation and Research (CDER) · CGMP
Excelvision - Fareva — CGMP/Finished Pharmaceuticals/Adulterated (issued 2026-06-25)
The FDA's Center for Drug Evaluation and Research issued a warning letter (320-26-98) to Excelvision - Fareva on June 25, 2026, following an inspection of its Annonay facility (FEI 3007058211) from January 12-22, 2026, citing significant Current Good Manufacturing Practice violations for finished pharmaceuticals. The firm failed to conduct thorough investigations of sterile drug product contamination complaints spanning three years, including nine non-sterility events involving mold, black specks, and discoloration; inadequately assessed environmental and personnel monitoring data linking identified microorganisms (such as Alternaria alternata) to manufacturing areas; and largely attributed contamination to customer mishandling without scientific evidence, rendering drug products adulterated under 21 CFR parts 210-211 and the FD&C Act. The FDA found the firm's proposed corrective actions inadequate, specifically rejecting its explanation for how contamination occurred in products released as sterile and expressing concern about container-closure system suitability.
Read the full letter on fda.gov →
critical · Center for Drug Evaluation and Research (CDER) · CGMP
Wizcure Pharmaa Private Limited — CGMP/Finished Pharmaceuticals/Adulterated (issued 2026-06-24)
FDA Center for Drug Evaluation and Research issued Warning Letter 320-26-97 to Wizcure Pharmaa Private Limited on June 24, 2026, following a December 3-10, 2025 inspection of its finished pharmaceutical manufacturing facility in Bhiwadi, Rajasthan, India, citing systematic Current Good Manufacturing Practice violations including falsified microbiological testing data, replacement of contaminated microbial plates with clean ones, pre-filled laboratory forms with test results, failure to collect required environmental and personnel monitoring samples, and unreliable microbial counts that compromised sterility assurance for aseptic processing. The FDA determined the facility's drug products are adulterated due to inadequate data integrity practices, suspended manufacturing, and requested comprehensive independent assessments of laboratory and documentation systems with detailed corrective and preventive action plans addressing organizational causes of the breaches.
Read the full letter on fda.gov →
critical · Center for Drug Evaluation and Research (CDER) · Unapproved drug
LyfeUnit / www.lyfeunit.com — Unapproved New Drugs/Misbranded (issued 2026-06-23)
On June 23, 2026, the FDA Center for Drug Evaluation and Research (CDER) issued a warning letter to LyfeUnit (www.lyfeunit.com, FEI 3043544191) citing violations of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and misbranded ketamine drug products into interstate commerce, including products marketed for mental health treatments without FDA approval. The FDA stated that certain ketamine products offered on the website (such as "Rotexmedica Ketamine 500mg/10ml Vials") lack approved applications under section 505 of the FD&C Act, despite FDA-approved ketamine versions existing on the market as Schedule III controlled substances, and requested that LyfeUnit cease offering such unapproved and misbranded drugs to U.S. consumers.
Read the full letter on fda.gov →
